This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Efficacy of rivastigmine on executive function in patients with Parkinson’s disease dementia


Schmitt, Frederick A., Farlow, Martin R., Meng, Xiangyi, Tekin, Sibel, Olin, Jason T.


CNS Neuroscience & Therapeutics, Volume: 16, No.: 6, Pages.: 330-336

Year of Publication



Background and Objective: Rivastigmine is approved in the USA for the treatment of mild to moderate Alzheimer’s disease and Parkinson’s disease dementia (PDD). Executive function (EF) deficits are a core symptom of PDD. The current objective was to investigate the effects of rivastigmine capsules versus placebo on EF in PDD, focusing on secondary outcome measures from a large, international, randomized, double-blind, placebo-controlled, 24-week trial (EXPRESS, CENA713B2311).; Methods: Secondary outcomes included Delis-Kaplan Executive Function System (D-KEFS) measures of EF. Data from three D-KEFS subtests (Card Sorting, Letter Fluency, Color-Word Interference), plus the Symbol Digit Modalities Test were analyzed in the observed case (OC) population. Changes from baseline in the rivastigmine versus placebo groups were evaluated using the van Elteren test blocking for country.; Results: Of 541 patients in the EXPRESS study, 402, 71, 97, and 65 patients provided data for Letter Fluency, Card Sorting and Color-Word Interference subtests, and the Symbol Digit Modalities Test, respectively. On Letter Fluency, rivastigmine was associated with improvements in correct responses, set loss errors, and responses made (all P < 0.05), but not repetition errors. Higher Card Sorting recognition description score (P= 0.03), and more correct substitutions on the Symbol Digit Modalities Test (P= 0.02) were also recorded.; Conclusion: Rivastigmine was associated with significant improvements over placebo on EF tests evaluating flexibility of thinking, problem solving and planning in patients with PDD. These findings support the hypothesis that rivastigmine may affect frontal subcortical circuits, which potentially contributes to observed clinical improvement associated with EF.; © 2010 Blackwell Publishing Ltd.

Bibtex Citation

@article{Schmitt_2010, doi = {10.1111/j.1755-5949.2010.00182.x}, url = {}, year = 2010, month = {oct}, publisher = {Wiley-Blackwell}, volume = {16}, number = {6}, pages = {330--336}, author = {Frederick A. Schmitt and Martin R. Farlow and Xiangyi Meng and Sibel Tekin and Jason T. Olin}, title = {Efficacy of Rivastigmine on Executive Function in Patients with Parkinson{textquotesingle}s Disease Dementia}, journal = {{CNS} Neuroscience {&} Therapeutics} }


aged, complications, dementia, double-blind method, drug effects, drug therapy, etiology, executive, executive function, female, function, humans, male, neuroprotective agents, neuropsychological tests, parkinson disease, phenylcarbamates, problem solving, psychology, reading, rivastigmine, therapeutic use, thinking, treatment outcome

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime